Nebie O, Devos D, Vingtdeux V, Barro L, Devedjian J, Jonneaux A, et al. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. J Biomed Sci. 2019;26:89 pubmed publisher

Sampera A, Sánchez Martín F, Arpi O, Visa L, Iglesias M, Menendez S, et al. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Mol Cancer Ther. 2019;18:2135-2145 pubmed publisher

Chen M, Wang T, Lin H, Burnouf T. Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells. N Biotechnol. 2019;49:151-160 pubmed publisher

El Bagdadi K, Kubesch A, Yu X, Al Maawi S, Orlowska A, Dias A, et al. Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept). Eur J Trauma Emerg Surg. 2019;45:467-479 pubmed publisher

Gao L, Zhang W, Zhong W, Liu Z, Li H, Yu Z, et al. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck squamous cell carcinoma. Oncol Rep. 2018;40:2558-2572 pubmed publisher

Mikuła Pietrasik J, Uruski P, Szubert S, Maksin K, Moszyński R, Szpurek D, et al. The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors. Biomed Res Int. 2017;2017:2592496 pubmed publisher

Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, et al. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer. 2018;21:84-95 pubmed publisher

Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev I, et al. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011;17:3619-30 pubmed publisher

Hickinson D, Marshall G, Beran G, Varella Garcia M, Mills E, South M, et al. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci. 2009;2:183-92 pubmed publisher

Gonzalez R, Seurynck Servoss S, Crowley S, Brown M, Omenn G, Hayes D, et al. Development and validation of sandwich ELISA microarrays with minimal assay interference. J Proteome Res. 2008;7:2406-14 pubmed publisher

Inoue Y, Miyamoto S, Fukami T, Shirota K, Yotsumoto F, Kawarabayashi T. Amphiregulin is much more abundantly expressed than transforming growth factor-alpha and epidermal growth factor in human follicular fluid obtained from patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2009;91:1035-41 pubmed publisher

Yotsumoto F, Yagi H, Suzuki S, Oki E, Tsujioka H, Hachisuga T, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 2008;365:555-61 pubmed

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10:39-50 pubmed

Sakai K, Yokote H, Murakami Murofushi K, Tamura T, Saijo N, Nishio K. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem J. 2006;397:537-43 pubmed